PDE5A and pulmonary arterial hypertension: At the Seventh World Symposium on Pulmonary Hypertension held in 2024, the use of inhaled treprostinil was recommended for patients classified as intermediate–low-risk on the basis of a four-strata risk assessment following initial combination therapy with an ERA and PDE5 inhibitor [5].